Skip to main content
. Author manuscript; available in PMC: 2019 Aug 15.
Published in final edited form as: Mol Cell Endocrinol. 2017 Sep 19;471:105–117. doi: 10.1016/j.mce.2017.09.024

Figure 1.

Figure 1

Expression of ESRRG and receptor target genes in Luminal A ILC. A, Tumor-derived ILC Signature (TIS) comprises top discriminant genes (50 up, 50 down) differentially expressed between Luminal A ILC and Luminal A IDC in the TCGA dataset from (Ciriello et al. 2015). Down-regulated genes in ILC vs. IDC include CDH1 and PTEN, which are mutated and deleted in ILC respectively. B, ESRRG mRNA expression is significantly higher in Luminal A ILC vs. Luminal A IDC in the combined METABRIC dataset in cBioPortal. Gene expression microarray data were compared by Mann-Whitney U test. C and D, mRNA expression of a four-gene ESRRG target signature is associated with poor outcome in Luminal A ILCs from TCGA (C) and METABRIC (D). mRNA levels are as measured by RNAseq (TCGA) or gene expression microarray (METABRIC), and high or low expression corresponds to above or below the median, respectively. Log-rank values calculated by cBioPortal.